Libia M. Lugo

FDA investigator

Appears on 24 documents from 2013 to 2024, mostly at sites in Puerto Rico. Most often cites production record review (21 CFR 211.192).

24
Documents on file
3.9
Observations per 483
2013
First seen
2024
Most recent

What they cite most

From 91 observations

Activity by year

2013: 2, 2015: 3, 2016: 1, 2017: 2, 2018: 2, 2019: 6, 2022: 2, 2023: 3, 2024: 3

Where

Puerto Rico 14 · Florida 5 · North Carolina 3 · South Carolina 1 · United Kingdom 1

Is Libia M. Lugo coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

24 documents, newest first
FirmOpen
483 Olympia Compounding PharmacyMay 29, 2024 · Orlando, Florida
483 Knoll LLCApr 18, 2024 · Jayuya, Puerto Rico
Amended 483 Baxter Healthcare CorporationFeb 9, 2024 · Marion, North Carolina
483 King Bio IncJul 28, 2023 · Asheville, North Carolina
483 FUJIFILM Diosynth Biotechnologies UK LtdMar 17, 2023 · Billingham, United Kingdom
483 Ambiopharm, Inc.Feb 9, 2023 · North Augusta, South Carolina
483 Teva Puerto Rico LLCNov 23, 2022 · Fajardo, Puerto Rico

About this profile

What does Libia M. Lugo inspect?

Libia M. Lugo appears on 24 documents on file covering 21 sites, mostly in Puerto Rico.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.160 and 21 CFR 211.22.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Libia M. Lugo is dated May 29, 2024.